Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Psychiatry/Psychology
Search Medical Condition
Psychosis Clinical Trials
A listing of Psychosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (1040) clinical trials
Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging
The study is trying to understand what causes bipolar disorder and how medications treat bipolar depression. If you participate, you will have two different brain scans (an MRI and a PET scan) and antidepressant treatment for free. We will then be able to see whether information on the brain scans ...
Early Alzheimers Disease
Enrolling men and women who have signs of early stage Alzheimer's Disease. The clinical trial is evaluating whether an investigational combined treatment slows down, arrests, or reverses early stage Alzheimer's disease.
Early Alzheimer’s disease
A global research study needs people aged 50 to 85 concerned by their memory changes. If you or someone you know is experiencing memory loss or has early Alzheimer’s disease, you may qualify and receive at no cost: Investigational drug Study-related care from a local study doctor Reimbursement for travel ...
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease
The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety ...
Cognite Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease
This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...
Cognitive Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease
This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
The main purpose of this study is to evaluate the efficacy of the study drug known as LY3314814 in participants with mild Alzheimer's disease (AD) dementia.
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia
The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia.
A Double-blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD). In addition, the study is designed to obtain pharmacokinetics (PK) data to guide dose selection for future pediatric studies of levomilnacipran.
